106 related articles for article (PubMed ID: 2547048)
21. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
[TBL] [Abstract][Full Text] [Related]
22. Breast carcinoma in women 35 years and younger: a pathological study.
Fernandopulle SM; Cher-Siangang P; Tan PH
Pathology; 2006 Jun; 38(3):219-22. PubMed ID: 16753742
[TBL] [Abstract][Full Text] [Related]
23. The intermediate filaments and prognostically oriented morphological classification in ductal breast carcinoma.
Rejthar A; Nenutil R
Neoplasma; 1997; 44(6):370-3. PubMed ID: 9605010
[TBL] [Abstract][Full Text] [Related]
24. An immunohistochemical examination of the expression of E-cadherin, alpha- and beta/gamma-catenins, and alpha2- and beta1-integrins in invasive breast cancer.
Gonzalez MA; Pinder SE; Wencyk PM; Bell JA; Elston CW; Nicholson RI; Robertson JF; Blamey RW; Ellis IO
J Pathol; 1999 Apr; 187(5):523-9. PubMed ID: 10398116
[TBL] [Abstract][Full Text] [Related]
25. Breast infiltrating ductal carcinoma: analysis of hormone, HER-2 receptors and Ki-67 proliferation marker.
Mustać E; Zamolo G; Petković M; Dordević G; Radić J; Grgurević E; Batinac T
Coll Antropol; 2008 Sep; 32(3):741-6. PubMed ID: 18982746
[TBL] [Abstract][Full Text] [Related]
26. [Immunohistochemical evidence of vimentin in fibrocystic breast disease and mammary carcinoma].
Alexiev B; Valkov I; Popov A
Zentralbl Pathol; 1992 Sep; 138(4):284-8. PubMed ID: 1329942
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer.
Nakopoulou LL; Alexiadou A; Theodoropoulos GE; Lazaris AC; Tzonou A; Keramopoulos A
J Pathol; 1996 May; 179(1):31-8. PubMed ID: 8691341
[TBL] [Abstract][Full Text] [Related]
28. Comparative study of monoclonal antibody B72.3 and gross cystic disease fluid protein-15 as markers of apocrine carcinoma of the breast.
Honma N; Takubo K; Arai T; Younes M; Kasumi F; Akiyama F; Sakamoto G
APMIS; 2006 Oct; 114(10):712-9. PubMed ID: 17004974
[TBL] [Abstract][Full Text] [Related]
29. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
Rakha EA; Putti TC; Abd El-Rehim DM; Paish C; Green AR; Powe DG; Lee AH; Robertson JF; Ellis IO
J Pathol; 2006 Mar; 208(4):495-506. PubMed ID: 16429394
[TBL] [Abstract][Full Text] [Related]
30. [Medullary carcinoma of the breast. Co-expression of keratin intermediate filaments and protein S-100 in tumor cells].
Puzzo L; Lanzafame S
Pathologica; 1989; 81(1074):433-9. PubMed ID: 2483260
[TBL] [Abstract][Full Text] [Related]
31. Relationship between hormone receptor status and tumour size, grade and comedo necrosis in ductal carcinoma in situ.
Barnes NL; Boland GP; Davenport A; Knox WF; Bundred NJ
Br J Surg; 2005 Apr; 92(4):429-34. PubMed ID: 15736216
[TBL] [Abstract][Full Text] [Related]
32. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
[TBL] [Abstract][Full Text] [Related]
33. Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables.
Barnard NJ; Hall PA; Lemoine NR; Kadar N
J Pathol; 1987 Aug; 152(4):287-95. PubMed ID: 3668731
[TBL] [Abstract][Full Text] [Related]
34. Vimentin expression in breast carcinomas.
Niveditha SR; Bajaj P
Indian J Pathol Microbiol; 2003 Oct; 46(4):579-84. PubMed ID: 15025348
[TBL] [Abstract][Full Text] [Related]
35. Cytosolic thymidine kinase is a specific histopathologic tumour marker for breast carcinomas.
He Q; Mao Y; Wu J; Decker C; Merza M; Wang N; Eriksson S; Castro J; Skog S
Int J Oncol; 2004 Oct; 25(4):945-53. PubMed ID: 15375544
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
[TBL] [Abstract][Full Text] [Related]
37. Vimentin expression in benign and malignant breast epithelium.
Heatley M; Whiteside C; Maxwell P; Toner P
J Clin Pathol; 1993 May; 46(5):441-5. PubMed ID: 7686566
[TBL] [Abstract][Full Text] [Related]
38. Immunohistological determination of oestrogen receptor, progesterone receptor, and intermediate filaments in Leydig cell tumours, Leydig cell hyperplasia, and normal Leydig cells of the human testis.
Düe W; Dieckmann KP; Loy V; Stein H
J Pathol; 1989 Mar; 157(3):225-34. PubMed ID: 2466972
[TBL] [Abstract][Full Text] [Related]
39. Vimentin expression is not associated with poor prognosis in breast cancer.
Seshadri R; Raymond WA; Leong AS; Horsfall DJ; McCaul K
Int J Cancer; 1996 Jul; 67(3):353-6. PubMed ID: 8707408
[TBL] [Abstract][Full Text] [Related]
40. Vimentin expression in 98 breast cancers with medullary features and its prognostic significance.
Holck S; Pedersen L; Schiødt T; Zedeler K; Mouridsen H
Virchows Arch A Pathol Anat Histopathol; 1993; 422(6):475-9. PubMed ID: 8392769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]